Bio-Rad Laboratories Class B
BIO.B
10 hedge funds and large institutions have $2.75M invested in Bio-Rad Laboratories Class B in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
45% more capital invested
Capital invested by funds: $1.9M → $2.75M (+$858K)
11% more funds holding
Funds holding: 9 → 10 (+1)
0.01% more ownership
Funds ownership: 0.11% → 0.12% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPCM
Osborne Partners Capital Management
San Francisco,
California
|
+$201K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$464 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CL
1
CSS LLC
Chicago,
Illinois
| $885K | – | – | – |
|
2
Renaissance Technologies
New York
| $882K | – | – | – |
|
3
Morgan Stanley
New York
| $343K | – | – | – |
|
|
BSW
4
Buckingham Strategic Wealth
Clayton,
Missouri
| $313K | – | – | – |
|
|
OPCM
5
Osborne Partners Capital Management
San Francisco,
California
| $206K | +$201K | +434 | New |
|
|
WT
6
Whittier Trust
South Pasadena,
California
| $74.3K | – | – | – |
|
7
Wells Fargo
San Francisco,
California
| $26K | – | – | – |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $23.7K | – | – | – |
|
|
PB
9
Pinnacle Bancorp
Beatrice,
Nebraska
| $1.39K | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$14.8K | -36 | Closed |
|
|
ECM
11
ExodusPoint Capital Management
New York
| – | +$464 | +1 | New |
|
BIO.B Hedge Fund Activity: Q1 2023 in Review
10 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class B (BIO.B) for Q1 2023, worth a combined $2.75M — up 45% from $1.9M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BIO.B positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Osborne Partners Capital Management, opening a new position worth an estimated $201K. The largest seller was UBS Group, exiting entirely with an estimated $14.8K sold.
- 10 institutional investors held Bio-Rad Laboratories Class B (BIO.B) as of Q1 2023, up from 9 in Q4 2022.
- Funds reported $2.75M of Bio-Rad Laboratories Class B stock for Q1 2023, up 45% quarter-over-quarter.
- 2 funds opened new Bio-Rad Laboratories Class B positions in Q1 2023 and 1 closed out, a net change of +1 holder.
- The largest Bio-Rad Laboratories Class B buyer in Q1 2023 was Osborne Partners Capital Management, an estimated $201K added.
- The largest Bio-Rad Laboratories Class B seller in Q1 2023 was UBS Group, an estimated $14.8K sold.
Based on aggregated 13F filings for Q1 2023.